HIF1A and neoplasm: The effects of ACF on cancer cells were first reported 50 years ago22, but research interest peaked in 2009, when a study of 336 drugs singled out ACF as the most potent HIF-1α inhibitor with effective tumor growth inhibition in a prostate cancer model20.